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EP-1202  
CBCT in Lung FFF-SABR: predictive parameters of early 
response 
F. Alongi
1Ospedale Sacro Cuore Don Calabria, Radiation Oncology, 
Negrar - Verona, Italy 
1, R. Mazzola1, F. Ricchetti1, N. Giaj Levra1, S. 
Fersino1, G. Sicignano1, A. Fiorentino1, R. Ruggieri1 
 
Purpose or Objective: aim of the study was to analyze tumor 
volume variations, by contouring on cone-beam computed 
tomography (CBCT) images, to evaluate early predictive 
parameters of Flattening Filter Free Stereotactic Ablative 
Radiation Therapy (SABR) treatment response. 
 
Material and Methods: the prescribed dose of SABR varied 
according to the tumor site (central or peripheral) and 
maximum diameter of the lesions using a strategy of risk-
adapted dose prescription with a range of dose between 48 
and 70 Gy (3-10 consecutive fractions). For the purpose of 
the analysis, gross tumor volume (GTV) was re-contoured for 
each patient at first and last CBCT using two lung 
levels/window: 1) -600/1000 Hounsfield Units (HU) and 2) -
1000/250 HU. Statistical analysis was performed to evaluate 
correlations between target variations on CBCT, using the 
two window-levels, and treatment response three months 
after the end of SABR. The analysis was conducted 
considering the following variables: number of fractions ≥ 5, 
BED 95-110, BED > 110 and GTV volume pre-SABR > 6 cc. 
 
Results: 41 lung lesions were evaluated. The median follow-
up was 14 months (range, 5 - 43 months). For both the CBCT 
level/windows, GTV shrinkage of at least 20% was associated 
to the probability of achieving a disease complete response 
(CR) at 3 months. The probability of CR ranged between 6 
and 8 times higher, in respect to the CBCT lung level 
adopted, comparing to patients without a GTV decrease of 
20%. This cut-off value was confirmed for all the variables 
analyzed. 
 
Conclusion: according to current findings, a tumor shrinkage 
cut-off of at least 20% at last session of SABR is predictable 
for CR 
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oligorecurrence within a mediastinal lymph node 
H.H. Wang
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Purpose or Objective: This study was to evaluate the safety 
and efficacy of stereotactic radiation therapy (SRT) in the 
treatment of patients with oligometastases or 
oligorecurrence within a mediastinal lymph node (MLN). 
 
Material and Methods: Between October 2006 and May 2015, 
patients with oligometastases or oligorecurrence within MLNs 
originating from different primary tumor were enrolled and 
treated with SRT at our hospital. The primary end-point was 
MLN local control (LC). Secondary end-points were: time to 
symptom alleviation; overall survival after SRT (OS); and 
toxicity using the Common Terminology Criteria for Adverse 
Events (CTCAE v4.0). 
 
Results: Eighty-five patients with 98 MLN oligometastases or 
oligorecurrence were treated with SRT. For the entire 
cohort, the 1-year and 5-year actuarial LC rates were 97.3% 
and 77.2%, respectively. Symptom alleviation was observed in 
28 patients (28/32, 87.5%), with symptomatic lesions after a 
median of 5 days (range, 3-30 days). The median OS were 
27.17 months for all patients and 32.20 months for those with 
NSCLC. Univariate and multivariate analyses revealed that an 
interval between diagnosis of primary tumors and SRT and 
MLN PTV volume were independent prognostic factors for OS 
in patients with NSCLC. CTCAE v4.0 ≥ Grade 3 toxicities 
occurred in six patients (7.06%), with Grade 5 in three 
patients (all with radiotherapy history to MLN station 7). 
Conclusion: SRT is a safe and efficacious treatment modality 
for patients with oligometastases or oligorecurrence to MLN, 
except for patients who received radiotherapy history to MLN 
station 7. Further investigation is warranted to identify the 
patients who benefit most from this treatment modality. 
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Purpose or Objective: Lung SBRT has shown excellent local 
control rates for inoperable patients with early-stage lung 
cancer without lymph node involvement. The reported 
toxicity is low, but factors associated with toxicity such as 
pneumonitis or lung fibrosis have not been well documented. 
 
Material and Methods: All inoperable patients treated in our 
institution between August 2007 and April 2013 with SBRT for 
peripheral early-stage lung cancer were included. Endpoints 
of the study were rib fracture, acute pneumonitis, lung 
fibrosis, hemoptysis. Univariate binary logistic regressions 
were used to look for statistical associations between binary 
(eg, gender), ordinal (eg, age, dose per fraction, total dose, 
number of treatment session, V20, mean lung dose, volumes) 
or nominal (eg tracking method, previous treatment) 
variables and the study endpoints. Multivariate logistic 
regression was to be performed if more than 1 factor was 
associated with 1 of the outcomes of interest with a P value 
of less than .2. Treatment fractionation regimens were 
adapted according to tumor localization. 
 
Results: 205 patients with 214 lesions were included in the 
study (67 central and 147 peripheral). 73 patients (36%) had 
toxicities: 14 patients (6.8%) had acute pneumonitis and 56 
lung fibrosis (27.3%) without clinical effects. Two patients 
had a rib fracture (1%) and 1 patient had rib cage pains. No 
other toxicities were observed. In univariate analysis, a lower 
number of treatment sessions (p=0.018) and higher dose per 
fraction (p=0.011) were associated with more toxicity. Longer 
treatment sessions were associated with more acute 
pneumonitis (p=0.001). Lung fibrosis was associated with a 
higher dose per fraction (p=0.027). Tracking was also 
associated with a higher rate of lung fibrosis, but patients 
treated with tracking had bigger tumors (mean diameter : 
21.9 mm vs 28 mm). Tumor localization (central vs 
peripheral) was not a predictive factor of toxicity. 
 
Conclusion: A higher dose per fraction and fewer treatment 
sessions were associated with more toxicity. Tumor 
localization was not associated with toxicity, suggesting that 
treatment regimens adapted for central tumors are efficient 
in minimizing toxicity. 
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Purpose or Objective: To describe the pattern of recurrence 
in resected pN1 non-small cell lung cancer (NSCLC), aiming to 
identify clinical, pathological, treatment and nodal factors 
predicting an increased risk of locoregional recurrence (LR) 
or distant metastasis (DM), in order to define a selected 
population who may benefit of postoperative radiotherapy 
(PORT). 
S572                                                                                                                                                  ESTRO 35 2016 
_____________________________________________________________________________________________________ 
Material and Methods: All patients who underwent surgery 
for NSCLC with pathologically confirmed N1 disease at the 
Spedali Civili Hospital of Brescia between 2001-2011 were 
identified. Patients with positive surgical margins, 
undergoing neoadjuvant treatment or PORT were excluded. 
LR was defined as first event of recurrence at the surgical 
bed, ipsilateral hilum or mediastinum, other sites were 
considered as DM. Kaplan-Meier actuarial estimates of overall 
survival (OS), progression free survival (PFS), freedom-from 
LR (FFLR) and freedom-from DM (FFDM) in different 
subgroups were compared with the log-rank test. The Cox 
proportional hazard regression model was used for 
multivariate analysis. 
 
Results: Among 285 patients who underwent surgery during 
the interval, 202 met the inclusion criteria. Clinical 
pathological, treatment and nodal factors are reported in 
table 1. Twenty four percent received adjuvant 
chemotherapy. The median follow-up was 39 months. The 
total number of recurrences was 118 (64.4%): 44 (24%) and 74 
(40.4%) for LR and DM, respectively. 5-year OS and PFS rates 
were 39,2% and 33,3%, respectively. Patients with 
recurrences experienced a statistically worse OS than 
patients without recurrences (p<0.001) and patients with DM 
had in turn OS rates significantly worse than those with LR 
(Figure 1). At multivariate analysis, extra capsular extension 
(ECE) (RR 2.10 p 0.01) and lymph nodal ratio (LNR)> 0:15 (RR 
1.68, p = 0.015) were associated with a worse PFS. ECE and 
LNR> 0,15 were significantly related to a worst FFLR (RR 3.04 
and 4.42, respectively), adenocarcinoma to an unfavorable 
FFDM (RR 1.97, p = 0.013). 
 
 
 
 
Conclusion: LR are common in pN1 NSCLC patients. Nodal 
factors as high LNR and ECE can predict an increased risk of 
worse FFLR and PFS. Prospective data on selected patients, 
treated with modern radiotherapy techniques, need to be 
collected to re-evaluate the role of radiotherapy. 
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Purpose or Objective: To verify adequacy of dose volume 
constraints reported in literature about stereotactic 
radiotherapy (SBRT) and radiosurgery of thoracic area. This 
study is based on the toxicity recorded in organs at risk 
(OARs) of patients enrolled in dose-escalation trials. 
 
Material and Methods: This is a retrospective study 
evaluating treatment plans of neoplasms in thoracic area. All 
55 patients were treated between November 2009 and 
December 2013 using SBRT (37 pt) or SBRS (18 pt). Prescribed 
doses were 30-35 Gy in 5 fractions in SBRS treatments and 16-
28 Gy in single fraction in SBRS treatments. All patients 
underwent radiotherapy with V-MAT technique. Main OARs 
were heart, oesophagus, and ribs with suggested Dmax of 35 
Gy, 32.5 Gy and 32.5 Gy in SBRT treatment, respectively, and 
22 Gy, 15 Gy and 30 Gy in SBRS treatment, respectively. 
Plans were evaluated by DVH analysis. Dosimetric data were 
compared with clinical data on early and late toxicity.  
 
 
 
Results: SBRT treatment: considering heart, oesophagus and 
ribs, Dmax constraints were exceeded in 7/37 patients 
(18.9%), 4/37 (10.8%) and 16/37 (43.2%) respectively. In 
these patients results about OARs were as follow: heart Dmax 
36.6-50 Gy, V35 0.5-4.7 cc; oesophagus Dmax 35.7-41.3 Gy, 
V32.5 0.1-0.9cc; ribs Dmax 35.7-52.5 Gy, V32.5 0.1-7.9cc. 
SBRS treatment: dose on heart and ribs exceeded Dmax 
constraints in 1/18 patients (5.6%) with a Dmax of 23.3Gy 
(V22=0.6cc) and 33.6Gy (V30=0.3cc) respectively. With a 
median follow up of 18 months considering SBRT treatment 
and 16 months considering SBRT, no Grade >2 (CTCAE 4.3), 
early or late toxicity of heart or ribs was reported. In SBRT 
group, 1 grade 2-oesophagus toxicity in a patient exceeding 
DMax constraint was registered. 
 
Conclusion: Patients irradiated did not develop severe 
toxicity on heart, oesophagus, and ribs although the 
administered doses were above constrains proposed in 
literature. A prolonged follow up and a larger population are 
needed to confirm the safety of dose-volume constraints 
